Rare diseases
Investigational molecules
Locations
Carolastrasse 2, Zentrum, 09111 Chemnitz, Germany
Pharmakologisches Studienzentrum Chemnitz GmbH in Chemnitz, Germany specialises in clinical trials of conditions such as Major depression, Migraine, Dementia Alzheimer's type, Agitation, and other specialisations. This site conducts important research.
At Pharmakologisches Studienzentrum Chemnitz GmbH, researchers are investigating treatments for disorders of the central nervous system. Current efforts include studies on Parkinson's disease tremor to improve motor performance. Another focus is the long‑term safety of therapies for multiple sclerosis. Preventive approaches for migraine, both episodic and menstrual, are also being evaluated. Early‑stage Alzheimer's disease with inflammatory biomarkers is examined to preserve cognition.
These studies aim to test new therapeutic agents and gather safety data, positioning the Chemnitz centre as a hub for innovative neurology research.
The centre conducts extensive research on major depressive disorder and related mood conditions. One trial assesses an adjunctive agent to prevent relapse in patients with anhedonia. A separate study evaluates the efficacy of a phytopharmaceutical for mild to moderate depression. Genetic profiling using the V1b polygenic score guides personalized antidepressant therapy. Safety and tolerability of novel serotonergic modulators are being characterized in participants with anxious distress.
By integrating pharmacologic innovation with patient‑centered outcomes, the site contributes to advancing mental health therapeutics.
While primarily focused on neurology, the site also addresses musculoskeletal aspects of neurological disease. Tremor reduction studies in Parkinson's disease consider muscle control and functional mobility. Research on multiple sclerosis includes evaluation of treatment‑related motor side effects. Patients with migraine are examined for headache‑induced neck and shoulder discomfort.
The interdisciplinary approach supports comprehensive management of movement‑related symptoms.
Clinical trials currently enrolling participants at this site.
Study of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo
GermanyA study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease
GermanyA Study of SPT-300 Compared to Placebo for Adults with Major Depressive Disorder with or without Anxious Distress
GermanyA Study of Brexanolone Caprilcerbate for Adults with Major Depressive Disorder With or Without Anxious Distress
GermanyStudy of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease
GermanyStudy of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants
GermanyStudy on the Safety and Effectiveness of MEDI0618 for Reducing Migraine Days in Adults with Episodic Migraine
GermanyTesting Ulotaront Added to Antidepressants for Adults with Major Depressive Disorder Who Did Not Respond Well to Initial Treatment
GermanyStudy of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo
GermanyStudy on Atogepant for Preventing Menstrual Migraine in Women
GermanyStudy on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder
GermanyStudy on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia
GermanyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
